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LEGALIZED IMPORTATION OF CANADIAN
PRESCRIPTION DRUGS: SHORT-TERM SOLUTION
TO A LONG-TERM PROBLEM
Adam T. Teufel*
Ensuring safe and effective prescription drugs for all Americans is the
central mission of the U.S. Food & Drug Administration (FDA), the agency
charged with regulating prescription drugs in the United States. l However,
"a prescription drug is neither safe nor effective to an individual who cannot
afford it." 2 This is the crux of a growing debate in the United States, not
only in Washington, but also among those who depend on prescription drugs
throughout the country. The Medicare Prescription Drug Improvement and
Modernization Act of 20033 authorized, among other things, importation of
prescription drugs if the FDA certifies that imported drugs pose no
additional risk to the safety of Americans and provide significant cost
savings.4 But can and should the FDA certify that imported drugs maintain
the "gold standard" 5 of drug safety and efficacy currently enjoyed by
Americans? If a legitimate, legalized infrastructure is developed to facilitate
* J.D. Candidate May 2006, The Catholic University of America, Columbus School of
Law, B.B.A. 2001 Emory University. The author wishes to thank his family and friends
for their support during law school, Fred H. Degnan for his feedback during the drafting
of this Comment, and the editors and staff of the Journal for their diligent efforts.
1. U.S. FOOD & DRUG ADMIN., FDA's MIssioN STATEMENT, available at
http://www.fda.gov/opacom/morechoices/mission.html.
2. Pharmaceutical Market Access and Drug Safety Act of 2004, S. 2328, 108th
Cong. §2(3) (2004) [hereinafter Dorgan-Snowe].
3. Pub. L. No. 108-173, 117 Stat. 2066 (codified at 42 U.S.C. § 1305 nt
(2005))[verify this citation/cite to current statute in force][its codified at various sections
throughout Title 42, beginning with 1305, various sections of Title 21, beginning with
355, Titles 5, 10, 20, 25, 26, 29, 31, 35, 45, 48].
4. Pub. L. No. 108-173, §§ 1121 - 1123, 117 Stat. 2464, 2469, (codified at 21
U.S.C. §§ 331, 333, 381, 384).f{cite to current statute in force}.
5. See infra Part 11 for a detailed discussion of FDA regulation of new drug
approval and post-market controls. The thorough nature of the regulatory scheme
promulgated by FDA has rightfully earned the agency the moniker "gold standard."
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the safe importation of price-controlled drugs from Canada, will this added
infrastructure negate any cost-savings? Will any form of price controls
ultimately stifle research and development of new, potentially life-saving
drugs? These are difficult questions Congress, administrative agencies, task
forces, political commentators, advocacy groups, and others have tried to
answer.
Part I of this comment examines the nature of the problem by introducing
the prescription drug importation debate, the current scope of illegal
importation, and current state and local government efforts to facilitate
illegal importation. Part II discusses the FDA's role in regulating drug
safety and efficacy. Part II examines some unintended consequences of
legalized importation such as decreased spending on research and
development of new drugs. Part IV lays out competing legislative proposals
to legalize importation which are pending in Congress. Part V is an analysis
of the costs and benefits of all of the above. Finally, Part VI argues that
Congress should not jeopardize drug safety and efficacy by legalizing
importation.
I. RISING COST OF PRESCRIPTION DRUGS LEADS TO INEVITABLE BACKLASH
A. Background
As recently as the 1930s, 6 it was common for large quantities of
pharmaceuticals to be marketed and dispensed which were ineffective and
unsafe.7 But with the modem era of pharmaceutical development, from the
invention of penicillin and a cure for polio to improvements in the treatment
of cancer and HIV, scientific research and development has significantly
advanced the treatment of disease and the efficacy of medicine. 8 Subsequent
discoveries of new drugs have allowed doctors to comfort the sick and treat
a range of human ailments.
9
With the advent of modem research and development of new drugs in the
1930s, Congress realized the need for government oversight of prescription
6. Carol Ballentine, Taste of Raspberries, Taste of Death: The 1937 Elixir
Sulfanilamide Incident, FDA CONSUMER, June 1981, available at http://www.fda.gov/oc/
history/elixir.html.
7. HHS TASK FORCE ON DRUG IMPORTATION, U.S. DEPT. OF HEALTH & HUMAN
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drug manufacturing and distribution to ensure patient safety.' 0 The Federal
Food, Drug, and Cosmetic Act of 1938,1 as amended, vested oversight
authority in the newly created FDA. The FDA is charged with ensuring that
each drug manufactured and distributed in the U.S. is safe and effective,
whether it originates domestically or is imported.' 2 The emergence and
recognition of imported counterfeit drugs in the 1980s led Congress to pass
the Prescription Drug Marketing Act of 1987 (PDMA).' 3 The PDMA, in
part, provided the FDA with greater authority over domestic wholesalers.
15
The reimportation provision of the Act prohibited anyone other than the
manufacturer, including wholesalers, from reimporting prescription drugs
that had been originally exported.
16
There are currently only two kinds of legally imported prescription drugs:
1) drugs manufactured in foreign facilities that meet FDA standards and pass
FDA inspections, and 2) drugs manufactured domestically, exported, then
reimported by the manufacturer pursuant to FDA regulations.' The FDA
subjects both types of imported prescription drugs to a stringent regulatory
regime. The regulations mandate costly and time-consuming drug testing to
ensure that U.S. drug regulations meet the "gold standard."' 8
When consumers turn to the Internet or domestic storefronts promising
"Drugs from Canada," they often receive drugs manufactured in various
foreign facilities. The FDA has not inspected, has no relationship with, and
therefore cannot ensure the safety and efficacy of drugs manufactured in
these foreign facilities. 19 Regulators have become concerned about the lack
of oversight and the increased ease with which consumers now import drugs.
Manufacturing specifications, processes, and distribution integrity are all
10. U.S. FOOD & DRUG ADMIN., HISTORY OF THE FDA: DRUGS AND FOODS UNDER
THE 1938 ACT AND ITS AMENDMENTS, http://www.fda.gov/oc/history/historyoffda/
section3.html.
11. 21 U.S.C. § 301 (2005).
12. HHS TASK FORCE ON DRUG IMPORTATION, supra note 7, at VII.
13. Id.
14. Prescription Drug Marketing Act of 1987, Pub. L. No. 100-293, 102 Stat. 95
(codified as amended at 21 U.S.C. §§ 301 Note, 333, 353 Note, 381 (2005)).
15. Id. at 21 U.S.C. § 353.
16. HHS TASK FORCE ON DRUG IMPORTATION, supra note 7, at VII-VIII.
17. Id. at VIII.
18. FRED H. DEGNAN, FDA's CREATIVE APPLICATION OF THE LAW, 72-74 (2000);
HHS TASK FORCE ON DRUG IMPORTATION, supra note 7, at VIII.
19. HHS TASK FORCE ON DRUG IMPORTATION, supra note 7, at VIII.
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unknown quantities to the FDA when consumers go outside the "closed"
domestic distribution system to import foreign drugs.
20
FDA inspectors are empowered to examine imported drugs at the border
to ensure they meet the agency's standards for safety and efficacy.
21
Unfortunately, such review is limited by manpower, budgetary, and
logistical constraints.22 The FDA faces an uphill battle in inspecting
i - 23
imported drugs because of the increase in both demand and availability
of24 imported drugs due to the Internet and mail-order foreign pharmacies.
Federal law and policy, as implemented by the FDA, requires that all
drugs be safe and effective, whether produced domestically or imported
25pursuant to FDA oversight. The process through which a drug is produced
is carefully scrutinized and tracked as it moves through our "closed"
distribution system. 26 The FDA's authority and resources must be greatly
expanded to allow for legalized drug importation. 27 Foreign governments
would need to play a larger support role by working with the FDA to ensure
foreign drug safety and efficacy, and overseeing foreign Internet sites over
which U.S. authorities do not have jurisdiction.
29
American citizens have always traveled abroad, and by necessity or
otherwise, sometimes return home with foreign drugs. 30  Although
technically illegal, the FDA has a policy of not seizing small quantities of
20. Id.
21. See generally Federal Food, Drug, and Cosmetic Act of 1938, 21 U.S.C. § 301
(2005); see also HHS TASK FORCE ON DRUG IMPORTATION, supra note 7, at VIII.
22. HHS TASK FORCE ON DRUG IMPORTATION, supra note 7, at VIII.
23. See Kristen Gerencher, More Americans Take Prescription Drugs,
CBS.MARKETWATCH.cOM, Dec. 3, 2004, http://www.marketwatch.com (search
"gerencher" and "prescription drugs") (last visited July 31, 2006).
24. See Internet Drugs, Hearing Before the Permanent Subcomm. on Investigations
of the S. Comm. On Governmental Affairs, 108th Cong. (2004) (statement of John M.
Taylor, I1, Associate Commissioner for Regulatory Affairs, U.S. Food and Drug
Administration), available at http://www.hhs.gov/asl/testify/t040722a.html ("[w]ith
greater and greater frequency, consumers are using the Internet to access health related
information and products. Sales of consumer products over the Internet have grown
rapidly, including the sale of drugs").
25. See generally Federal Food, Drug, and Cosmetic Act of 1938, 21 U.S.C. § 301
(2005); see also HHS TASK FORCE ON DRUG IMPORTATION, supra note 7, at VIII.
26. HHS TASK FORCE ON DRUG IMPORTATION, supra note 7, at VIII.
27. Id.
28. Id. at XI.
29. Id.
30. Id. at VIII.
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drugs intended for personal use. 31 This is a common-sense position that was
never controversial until recent years, when large numbers of citizens, due to
sharply rising drug costs, have turned to foreign pharmacies for more
affordable prescription drugs.
32
More than 40% of Americans regularly use prescription medication.33 As
prescription drug prices continually rise, easily surpassing the rate of
inflation, 34 many Americans are forced to look elsewhere for drugs. 35 Price-
controlled drugs in neighboring countries are an appealing alternative to
expensive domestic drugs. 36 With the advent of Internet sites and mail-order
pharmacies to supply this demand, importation is easier than ever and
continues to grow in popularity37 despite its illegality.
U.S. policy should promote access to safe, effective, and affordable
prescription drugs for all who require them. Unfortunately, in a free market
society these goals are often at odds with one another.38  Ensuring
affordability by imPorting price-controlled foreign drugs may compromise
safety and efficacy. However, a drug will do little good to an individual
31. See OFFICE OF REGULATORY AFFAIRS, U.S. FOOD & DRUG ADMIN., REGULATORY
PROCEDURES MANUAL MARCH 2006, available at http://www.fda.gov/ora/compliance
ref/rpmnew2/ch9pers.html (last visited July 31, 2006).
32. HHS TASK FORCE ON DRUG IMPORTATION, supra note 7, at IX.
33. Id.
34. See FISCAL POLICY INST., IMPOSSIBLE CHOICES: FOOD AND HOUSING OR
PRESCRIPTION DRUGS? (Oct. 2000), available at http://www.fiscalpolicy.org/Impossible
ChoicesSummary.htm.
35. HIHS TASK FORCE ON DRUG IMPORTATION, supra note 7, at IX.
36. Id.
37. John D. Jones, An Overview of the Legislation That Matters to Consultants and
Their Clients, PHARMACY BENEFIT INSIDER (Prescription Solutions, Costa Mesa, Cal.),
Sept. 2003, available at http://www.rxsolutions.com/c/pbi/pbi view.asp?docid=369.
38. See Malcolm Gladwell, High Prices: How to think about prescription drugs, THE
NEW YORKER, Oct. 25, 2004, available at http://www.gladwell.com/pdf/highprices.pdf
(pointing out that while pharmaceutical companies argue they need sustained high prices
to support research and development of new drugs, pharmaceuticals often "reengineer"
brand-name drugs about to go off-patent, to create a new brand-name, instead of
competing with lower-priced generics. The author acknowledges there are additional
actors contributing to the high price of prescription drugs ("physicians, insurers, patients,
and government officials" must reach a "consensus about what we want from our medical
system and how much we are willing to pay for it"). The author argues a consensus is
needed by all of these actors to encourage increased development of generics in order to
increase competition and choice, thus driving down prices, while maintaining a capitalist
price structure not dependent on price controls).
39. See generally HHS TASK FORCE ON DRUG IMPORTATION, supra note 7.
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who cannot afford it.40 This balancing act drives at the heart of the current
public debate. 41 Should Americans sacrifice the current "gold standard" of
safety and efficacy for drugs at any cost? Or, is it more important to ensure
the high standards, and in the process allow pharmaceutical companies to
price domestic drugs so high that many who need them must do without?
42
Congress has attempted to address these difficult questions by proposing
legislation legalizing importation,43 a seemingly short term solution to a long
term problem.
B. Scope of Illegal Importation
In 2003, it is estimated that approximately 12 million prescription drug
products, worth nearly $700 million, entered the U.S. illegally from
Canada.44 This vast illegal trade commenced via Internet sales, domestic
storefronts, and cross-border travel. An equivalent amount is estimated to
have arrived from other foreign countries by mail services.4 5 Importation
includes all forms and brands of drugs and increases exponentially every
46year. Some of the illegal products are reimported into the U.S. while
others are manufactured in foreign facilities; in nearly every case, the FDA
has not inspected the drug shipments or the facilities from which they
originated.
Internet pharmacies and personal purchases during trips abroad facilitate
drug importation from foreign countries. 48 Some internet pharmacies are
licensed at the state level and the majority dispense safe and effective
drugs.49  Unfortunately, many Americans in search of affordable drugs
eventually make their purchases through disreputable Internet or foreign
outlets, the most common example being foreign-based pharmacies
40. Dorgan-Snowe, supra note 2.
41. HHS TASK FORCE ON DRUG IMPORTATION, supra note 7, at IX.
42. See infra Part I.C.
43. See Patricia Barry & Barbara Basler, Battle Lines Drawn on Rx Imports, AARP
BULLETIN ONLINE, July 2004, http://www.aarp.org/bulletin/prescription/Articles/a2004-
06-22-reimportation.html.
44. HHS TASK FORCE ON DRUG IMPORTATION, supra note 7, at IX.
45. Id.
46. Marisa Navarro, Lawmakers Rip FDA Over Unapproved Import Drugs,
REUTERS, June 24, 2003, available at http://www.aegis.com/news/re/2003/RE030629.
html.
47. HHS TASK FORCE ON DRUG IMPORTATION, supra note 7, at IX.
48. Id.
49. Id.
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specializing in facilitating American drug importation. 50  Because foreign
pharmacies do not primarily serve Americans and are not subject to FDA
regulation, the safety and efficacy of such drugs is unknown, and often the
oversight is of lesser quality than the FDA "gold standard.' '" 5 This opens the
52door for potentially dangerous drugs to enter the U.S. market.
Of chief concern are so called "rogue" Internet pharmacies, unlicensed
outfits which falsely claim their drugs are interchangeable with the approved
U.S. versions.53 Certain drugs require special handling or are highly
susceptible to abuse by patients if prescribed improperly. 54 Others may be
sold non-sterile, counterfeit, or improperly packaged.5 5 Still others may be
shipped from foreign countries with questionable regulation and oversight
for safety and effectiveness. 56 In short, Americans who choose to import
from Internet pharmacies and unlicensed storefronts do so at their own risk.
C. Domestic drug supply too expensive
The stories in the media are dramatic. Senior citizens traveling north of
the border in search of affordable prescription drugs; 57 the elderly seeking58
drugs unused by friends or left by the deceased; splitting pills and other
59 . 60forms of rationing; foregoing food or rent payments to fill prescriptions.
Some specific examples recently reported in the press include: an 80 year
old woman taking eleven medications for cholesterol, high blood pressure
and heart problems for $1000 per month in the U.S. obtained the same
medications in Canada for $300 per month; 61 a 62-year-old woman suffering





54. Id. at IX-X.
55. Id.
56. Michelle Meadows, Imported Drugs Raise Safety Concerns, FDA CONSUMER,
Sept. 2002, available at http://www.fda.gov/fdac/features/2002/502_import.html.
57. Patricia Barry, Chasing Drugs: Many Readers Take Drastic Steps to Get





61. William M. Welch, Once just a trickle, Canada's Rx drugs pouring into USA,
USA TODAY, Oct. 6, 2003, available at http://www.usatoday.com/news/nation/2003- 10-
06-canada-drugs-usat-x.htm.
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month at her local pharmacy when the same drugs cost only $82 per month
in Canada;62 a retiree on a recent bus trip to Canada who wept upon
purchasing medication after doing without for months so his wife could
afford hers.63 There are countless other stories 64 all illustrating the fact that
millions are suffering as prescription drug prices spiral out of control.
It is estimated that up to two million Americans imported prescription
drugs in 2004.65 However, imports remain a fraction of the overall domestic
drug market, which exceeds $200 billion per year.66 The greatest threat to
pharmaceutical companies is the potential collapse of an unregulated price
structure which has allowed them to charge unlimited amounts domestically
while abiding by government price controls in foreign countries. 6' For
years, the pharmaceutical industry has reaped large profits domestically,
which in turn subsidizes the industry's ability to supply drugs overseas in
price-controlled markets.6 8
D. Canada supplies the demand
The U.S. is widely regarded as having one of the world's safest drug
supplies. 69 However, foreign supplies of prescription drugs are penetrating
the system and currently undermine FDA efforts to ensure drug safety and
efficacy. Numerous Internet sites and storefronts have opened to supply the
rising demand for more affordable prescription drugs from Canada:
CanadaPharmacy.com, CanadaDrugs.com, CanadaRx.com, RxNorth.com-
there are many more. As many Americans become fed up with the high cost
of domestic prescription drugs and turn to Canada for more affordable price-
controlled drugs, Internet sites fill the void.70 Currently, Internet purchases
62. Id.
63. Id.
64. See, e.g., Alliance for Retired Americans, Share Your Rx Story, at
http://www.retiredamericans.org/index.php?tg-articles&idx=More&topics= 18&article=2
99 (July 31, 2006, 3:00 EST).
65. See Barry & Basler, supra note 43.
66. See Alan Sager, Director M.P.H. Program, Boston University, Legislative
Briefing on Prescription Drug Reform (Nov. 23, 2004), available at http://dcc2.bumc.bu.
edu/hs/Leg_Brief MA St Hs 23 Nov%2004.doc (last visited July 31, 2006).
67. Id.
68. Id.
69. See HHS TASK FORCE ON DRUG IMPORTATION, supra note 7, at X.
70. See Ludmila Bussiki Silva Clifton, Comment, Internet Drug Sales: Is It Time to
Welcome "Big Brother" Into Your Medicine Cabinet?, 20 J. CONTEMP. HEALTH L. &
POL'Y 541, 541 (2004).
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are the most common way to import prescription drugs, but they are not the
only way.71
Traditionally consumers visit their neighborhood drugstore to fill
prescriptions. While the explosion of Canadian Internet sites has greatly
facilitated drug importation, some consumers are uncomfortable ordering
drugs from a nameless, faceless source. 72 "Brick and mortar" storefronts are
popping up across the U.S. to facilitate drug importation for those who
prefer not to use the Internet. These stores serve as middlemen in the drug
importation game. For a fee, the stores forward prescriptions written by
American doctors to Canadian pharmacies, who fill the prescriptions at the
lower price, then mail the prescription directly to the patient in the U.S.
73
These storefronts may be unlicensed and in some cases forward
prescriptions to unregulated third-world pharmacies instead of the promised
Canadian outlet.
74
E. State/Local government reaction
The search for cheaper drugs has stirred an international debate pitting
angry consumers and defiant state and local governments against the
pharmaceutical industry and the Federal government. State and local
governments, facing increasing deficits as they struggle to provide
prescription drug benefits to state employees and retirees, have turned to
drug importation as a means of lowering their health care budget. Minnesota
Governor Tim Pawlenty states, "Americans pay more for prescription
medicine than the rest of the world. The price differential puts prescription
medicine out of reach for too many people. The current situation is unfair
and cannot continue."
75
Minnesota is one of many states currently violating Federal law by
facilitating and, in some cases, subsidizing consumer importation of foreign
prescription drugs. Other states either implementing programs similar to
Minnesota or considering doing so include Oregon,
76 Rhode Island, 7
71. Id. at 543.
72. Welch, supra note 61.
73. Steve Miller, Storefronts Offering Low-Priced Drugs from Canada, WASH.
TIMES, Aug. 9, 2003, available at http://washingtontimes.com/national/20030809-
I 10416-8164r.htm.
74. See HHS TASK FORCE ON DRUG IMPORTATION, supra note 7, at IX - X.
75. Press Release, Tim Pawlenty, Governor of Minnesota (Jan. 2004), available at,
http://www.state.mn.us/cgi-bin/portal/mn/jsp/home.do?agency=Rx.
76. Carol Ukens, Oregon Eyes Rx Imports Through Pharmacies, DRUG Topics, Sept.
27, 2004, http://www.drugtopics.com/drugtopics/article/articeDetail.jsp?id=126095.
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Vermont, 8 Illinois,79 Wisconsin, New Hampshire,
81 and California. 82
Local jurisdictions have followed suit as well: Washington, D.C.,83 Boston,
Mass., Springfield, Mass., Montgomery, Ala., Caldwell County, N.C.,
8
7
77. Letter from William K. Hubbard, FDA Associate Commissioner, to Rhode Island
Gov. Donald L. Carcieri (July 1, 2004), available at http://www.fda.gov/oc/opacom/
hottopics/importdrugs/carcieri.pdf (FDA responded to pending legislation passed by the
Rhode Island General Assembly that would allow for the licensing of Canadian
pharmacies by the State of Rhode Island).
78. FDA Statement, U.S. Food & Drug Admin., Statement on Vermont's Lawsuit on
Importing Prescription Drugs from Canada (Aug. 20, 2004), available at
http://www.fda.gov/bbs/topics/news/2004/NEW0I 107.html.
79. Letter from Lester M. Crawford, FDA Acting Commissioner, to Illinois Gov.
Rod R. Blagojevich (June 3, 2004), available at http://www.fda.gov/oc/opacom/
hottopics/importdrugs/GovB63.pdf (FDA responded to Illinois governor's efforts to find
ways to help Illinois citizens save money by purchasing foreign prescription drugs).
80. Letter from William K. Hubbard, FDA Associate Commissioner, to Wisconsin
Gov. Jim Doyle (July 22, 2004), available at http://www.fda.gov/oc/opacom/hottopics/
importdrugs/doyle72204.html (FDA responded to reports received by the State of
Wisconsin from Canadian internet pharmacies participating in Wisconsin's Prescription
Drug Resource Center program showing drugs purchased through the program may be of
lesser quality then drugs approved for sale in the U.S.).
81. Letter from William K. Hubbard, FDA Associate Commissioner, to New
Hampshire Gov. Craig Benson (March 31, 2004), available at http://www.fda.gov/oc/
opacom/hottopics/importdrugs/benson.html (FDA responded to possible endorsement of
New Hampshire governor for the purchase by New Hampshire citizens of unapproved,
illegal drugs from a foreign pharmacy, specifically CanadaDrugs.com).
82. Letter from William K. Hubbard, FDA Associate Commissioner, to Gregory
Gonot, Deputy Attorney General of California (August 25, 2003), available at
http://www.fda.gov/opacom/gonot.html (FDA responded to California Attorney
General's Office inquiry about the potential liability associated with importing
prescription drugs from Canada).
83. Letter from William K. Hubbard, FDA Associate Commissioner, to Anthony
Williams, Mayor of Washington, D.C. (August 20, 2004), available at
http://www.fda.gov/oc/opacom/hottopics/importdrugs/williams.pdf (FDA responded to
D.C. government program to import prescription drugs from Canada).
84. Letter from William K. Hubbard, FDA Associate Commissioner, to Thomas M.
Menino, Mayor of Boston, Mass. (August 4, 2004), available at http://www.fda.gov/oc/
opacom/hottopics/importdrugs/menino0804.html (FDA responded to Boston program
that will encourage city employees and retirees to purchase foreign unapproved
prescription drugs).
85. Tim Craig, Savings Uncertain In Import Drug Plan: Questions Raised In
Montgomery, WASH. POST, Jan. 13, 2005, at B 1.
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and even Montgomery County, Md., 88 home of FDA headquarters. These
programs by defiant states and localities generate federalism and supremacy
clause issues, but, so far, the FDA has not interfered aside from the
occasional sternly worded letter.89 Not only would an FDA crack-down
prove politically unpopular, it would alienate state governments and
agencies which act as FDA's enforcement eyes and ears at the local level.
11. FDA: BROAD MISSION, LIMITED RESOURCES
The FDA has been described as a "small agency with a fine old tradition
dwarfed in both budget and political power by the pharmaceutical giants it is
being asked to police." 90 Federal law requires the FDA to ensure all drugs
manufactured and sold in the U.S. are safe and effective.9 1 The FDA's
exhaustive regulation of the nation's drug supply ensures Americans enjoy
92the "gold standard" of drug regulation. Regulations "govern the way in
which prescription drugs are manufactured, packaged, labeled, held, and
shipped., 93 The high rate of drug importation in the United States-some 24
million prescription drug products annually 94-means the various mail
services are receiving and delivering drugs to cities all across the United
States. If the FDA is required to take on regulation of the booming
importation trade, in addition to its current duties, it is unlikely the FDA
could effectively maintain the "gold standard" of drug regulation. If
Congress were to legalize importation and require the FDA to oversee the
86. Julie Appleby, More cities, states opt for Canadian drugs, USA TODAY, Dec.
23, 2003, available at http://www.usatoday.com/money/industries/health/drugs/2003-12-
23-canadadrugs x.htm.
87. Letter from William K. Hubbard, FDA Associate Commissioner, to Bobby
White, Manager of Caldwell County, N.C. (April 5, 2004), available at http://www.
fda.gov/oc/opacom/hottopics/importdrugs/white045O4.html (FDA responded at the
suggestion of the North Carolina Board of Pharmacy to reinforce concerns the Board
raised with the County Manager about Caldwell County's nascent Canadian drug
importation program for county employees and dependents that facilitates the purchase of
unapproved, illegal drugs from foreign pharmacies).
88. Craig, supra note 85.
89. See U.S. Food and Drug Administration, Importing Prescription Drugs, Letters to
State and Local Officials, http://www.fda.gov/importeddrugs (last visited July 31, 2006).
90. Christine Gorman, Can the FDA Heal Itself?, TIME, Feb. 28, 2005, at 58.
91. See generally Federal Food, Drug, and Cosmetic Act of 1938, codified at 21
U.S.C. § 301 (2005).
92. HHS TASK FORCE ON DRUG IMPORTATION, supra note 7, at X.
93. Id.
94. See HHS TASK FORCE ON DRUG IMPORTATION, supra note 7, at LX
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trade, such legislation would necessitate substantial new resources and tight
controls on which drugs enter the U.S.
The FDA has approximately 3,800 employees inspecting the U.S. drug
supply and only 450 actively investigating importation activities. 95 Only a
small percentage of FDA inspectors are available to inspect drug imports at
96the nation's international mail facilities. The increasing number of
imported drugs, coupled with limited manpower, means that most drugs
cross the border without inspection. 97 Despite the FDA's efforts to inspect
drug imports at the border, the FDA already has insufficient resources to
adequately inspect most illegally imported drugs today. In order to inspect
large scale commercial shipments, the FDA would likely require dramatic
increases in technology, personnel, and other resources. This leaves
personal use shipments unregulated and open to exploitation from foreign
pharmacies or distributors.
A. FDA Ensures Prescription Drugs are Safe and Effective
The FDA review process is lengthy one:
Today, the process of bringing a drug to a patient's bedside takes
an average of 8.5 years, costs about $500 million, and includes a
rigorous review.... FDA-approved drugs meet the highest scientific
standards and are demonstrated to be safe and effective. 98 Most
modem drug development starts in laboratories, where scientists
probe the effects of chemical compounds... involved in the disease
whose treatment they seek. The potentially effective chemicals are
then tested in two or more species of animals to determine whether
they can be safely used in humans.
99
Barely 1 in 1,0001potential drugs tested pass these initial trials and advance
to further studies.
Next, "[i]f the FDA finds the approach promising and an institutional
review board of scientists, ethicists, and health-care specialists approve the
sponsor's study protocol, the drug enters a progression of tests in
95. Id. at IX.
96. Id.
97. Id.
98. U.S. FOOD & DRUG ADMIN., FDA AND THE DRUG DEVELOPMENT PROCESS: How
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humans."10' Each new trial phase takes place only upon successful
completion of the previous trial phase:102
Phase I studies test the product for its adverse effects on a small
number of healthy volunteers.
Phase II studies probe the drug's effectiveness in patients who
have the disease or condition the product is intended to treat.
Phase Ill studies seek to determine the drug's safety, effectiveness
and dosage. In these trials, hundreds or thousands of patients are
randomly assigned to be treated either with the tested drug or a
control substance, most frequently a placebo.'
0 3
Finally, "[t]he results of Phase III trials are submitted to the FDA for
review by a team of.. specialists."' 0 4 This group of specialists' main
responsibility, often in consultation with an advisory panel of outside
experts, is to determine whether the trials have demonstrated substantial
evidence of the drug's safety and effectiveness. 10 5 And, "[o]nly products that
pass this test may be approved for marketing."' 1 6 FDA review typically
takes years and is often the target of criticism for what is perceived as
unnecessary delay and bureaucratic red tape.1
07
B. FDA Guidelines on Personal Importation
Any interstate shipment or importation of unapproved new drugs is a
violation of FDA regulations. 18 Unapproved new drugs include, "foreign-
made versions of U.S. approved drugs, that have not been manufactured in
accordance with and pursuant to an FDA approval."' 1 9 It is the importer's
101. Id.
102. Id. See also Degnan, supra note 18, at 72.
103. U.S. FOOD & DRUG ADMIN., FDA AND THE DRUG DEVELOPMENT PROCESS: How
THE AGENCY ENSURES THAT DRUGS ARE SAFE AND EFFECTIVE, supra note 98. See also
Degnan, supra note 18, at 73-74 (Phase I studies typically involve 20 to 100 participants.
Phase 1I studies usually involves several hundred patients. Phase Ill, the most time
consuming and demanding part of the process, can take up to four or five years).
104. U.S. FOOD & DRUG ADMIN., FDA AND THE DRUG DEVELOPMENT PROCESS: How
THE AGENCY ENSURES THAT DRUGS ARE SAFE AND EFFECTIVE, supra note 98.
105. Id.
106. Id.
107. See Degnan, supra note 18, at 74.
108. OFFICE OF REGULATORY AFFAIRS, U.S. FOOD & DRUG ADMIN., INFORMATION ON
IMPORTATION OF DRUGS PREPARED BY THE DIVISION OF IMPORT OPERATIONS AND POLICY,
available at http://www.fda.gov/ora/import/pipinfo.htm.
109. Id.
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obligation to demonstrate to the FDA that any drugs offered for importation
have been approved by the FDA."1
0
The FDA, in its administrative discretion, has made some exceptions. In
its Coverage of Personal Importations, the FDA developed guidance for the
"agency's enforcement priorities with respect to the personal importation of
unapproved new drugs by individuals for their personal use.""' This
guidance:
[I]dentifies circumstances in which FDA may consider exercising
enforcement discretion and refrain from taking legal action against
illegally imported drugs. Those circumstances are as follows:
1) the intended use [of the drug] is unapproved and for a
serious condition for which effective treatment may not be
available domestically either through commercial or clinical
means;
2) there is no known commercialization or promotion to
persons residing in the U.S. by those involved in the
distribution of the product at issue;
3) the product is considered not to represent an unreasonable
risk;
and
4) the individual seeking to import the product affirms in
writing that it is for the patient's own use (generally not more
than a 3 month supply) and provides the name and address of
the doctor licensed in the U.S. responsible for his or her
treatment with the product, or provides evidence that the
product is for the continuation of a treatment begun in a
foreign country."
2
But, "FDA's guidance is not.., a license for individuals to import
unapproved (and therefore illegal) drugs for personal use into the U.S."
113
And, "[e]ven if all of the factors noted in the guidelines are present, the
drugs remain illegal and FDA may decide that such drugs should be refused
entry or seized.""11 4 This advisory guidance represents FDA's current
110. Id.
111. OFFICE OF REGULATORY AFFAIRS, U.S. FOOD & DRUG ADMrN., IMPORTATION OF
PRESCRIPTION MEDICINES/DRUGS, available at http://www.fda.gov/ora/import/traveler
_alert.htm (implies enforcement efforts are focused on commercial shipments and
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enforcement priorities regarding personal importation but is subject to
change."1
5
Ill. IMPORTATION SIDE EFFECTS
A. Negative impact on U.S. drug supply
The U.S. drug distribution system is currently a "closed" system involving
only manufacturers, wholesalers, and pharmacies. 16 The manufacturing
process and distribution process are tightly regulated by the FDA. 117 This
extensive regulation at multiple levels drastically limits the possibility of
unsafe, ineffective drugs reaching consumers. The very nature of
prescription drugs (potentially harmful products) necessitates thorough
oversight by FDA which provides the "gold standard" in drug regulation.
Legislation legalizing importation would open the "closed" system and
would likely increase the risk that consumers would be harmed by unsafe
drugs.1 9 Questionable drug regulation in foreign countries and exploitation
of the distribution system are windows of opportunity for unsafe drugs to
penetrate the U.S. market.'
20
B. Unintended consequences of legalized importation
Consumers import prescription drugs to take advantage of foreign price-
controls and therefore, obtain drugs at a lower cost. Often, consumers seek
out foreign versions of FDA-approved drugs sold in the U.S. 12 1 However, in
any legalized importation system, once start-up and infrastructure costs are
factored in, it is estimated that actual savings to consumers will only account
for 1 to 2 percent savings relative to total U.S. drug spending. 122 Moreover,
any price savings passed on through drug importation would likely be
captured by intermediaries profiting from facilitating drug importation.
115. Id.
116. HHS TASK FORCE ON DRUG IMPORTATION, supra note 7, at X.
117. See supra Part 1 .A.
118. HHS TASK FORCE ON DRUG IMPORTATION, supra note 7, at X.
119. Id.
120. Id.
121. Id. at XI.
122. Id. at XI.
123. Id.
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It is widely reported that prices for generic drugs in the U.S. are much
lower then foreign generic drug prices.' 24 On average, foreign generic drugs
retail 50% higher then U.S. generic drugs. 25 Increased use of generic drugs
by U.S. consumers is one alternative way of lowering the cost burden of
prescription drugs. Another potential limitation on importation: drug
companies based in the U.S., 126as well as foreign governments, 127 could
limit drug supplies available for U.S. importation if faced with an onslaught
of Americans seeking affordable drugs through any legalized importation
system. 128
C. Effect on Research & Development
The concern most often voiced by the pharmaceutical industry in regards
to legalized drug importation is that any decrease in revenues will reduce
funding available for research and development of new drugs.' 2 9 Any shift
by American consumers away from purchasing expensive domestic drugs to
price-controlled foreign drugs leads to a decrease in revenues for
pharmaceutical companies. 130  Since the cost of bringing new drugs to
market would remain the same, while revenues fell, it is feasible that
pharmaceutical companies would cut spending on research and
development. Theoretically, if the industry proceeded in this manner and
chose not to cut spending elsewhere, research and development would
decrease and the flow of new drugs would slow. 132 It is estimated as many
as 18 new drugs per decade would fail to be developed if legalized
importation forces cuts in research and development. 133
124. OFFICE OF PLANNING, U.S. FOOD & DRUG ADMIN., FDA WHITE PAPER: GENERIC
DRUG PRICES IN THE U.S. ARE LOWER THAN DRUG PRICES IN CANADA (Nov. 2003),
available at http://www.fda.gov/oc/whitepapers/drugprices.html.
125. Id. See also HHS TASK FORCE ON DRUG IMPORTATION, supra note 7, at XI.
126. Patricia Barry, Crackdown in Canada: Drug Industry Giant Plays Hardball to
Halt Sales to U.S. Buyers, AARP BULLETIN ONLINE, Feb. 2004, http://www.aarp.org/
bulletin/prescription/Articles/a2004-02-03-crackdown.html.
127. Patricia Barry, Canada Dry?, AARP BULLETIN ONLINE, Feb. 2005,
http://www.aarp.org/bulletin/prescription/canada dry.html.
128. HHS TASK FORCE ON DRUG IMPORTATION, supra note 7, at XI.
129. Press Release, Paul Antony, Chief Medical Officer, Pharmaceutical Research and
Manufacturing of America, on Drug Importation Task Force Report (Dec. 21, 2004),
available at http://international.phrma.org/mediaroom/press/releases/21.12.2004.1108.
cfm.
130. Id.; HHS TASK FORCE ON DRUG IMPORTATION, supra note 7, at XII.
131. HHS TASK FORCE ON DRUG IMPORTATION, supra note 7, at XII.
132. Id.
133. Id.
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Any reduction in new drug development is likely to offset any financial
savings passed on to consumers via legalized drug importation. But many
disagree with the pharmaceutical industry's contention that high prescription
drug prices drive investment in research and development.'
34
The pharmaceutical industry's repetitious cry that research and
development would be curtailed if drug prices are moderated is
extraordinarily misleading. If meaningful steps are taken to ameliorate fast-
growing drug prices, it is corporate profits, expenditures on marketing, and
high executive compensation that are more likely to be affected, not research
and development.
35
Studies have shown that the pharmaceutical industry spends twice as
much on marketing, advertising, and administration than on research and
development. 36 Often cited as the most profitable industry in the 
U.S.,' 37
the pharmaceutical companies' annual net profits easily exceed expenditures
on research and development. 138  Despite this disparity in research and
development expenditures, 139 the pharmaceutical industry is a market leader
in executive compensation.
140
134. See Patricia Barry, Drug Profits vs. Research, AARP BULLETIN ONLINE, June
2002, http://www.aarp.org/builetin/medicare/Artices/a2003-06-23-drugprofitsvsresearch.
html. See also Pharmaceutical Companies Maintain Huge Profits with High-Priced
Pills, Issue Brief (Alliance for Retired Americans, Washington, D.C.), Aug. 2003,
available at http://www.retiredamericans.org/index.php?tg=fileman&idx=get&inl = 1 &id
= 1 &gr-Y&path=&file=profpills issuebrief final.pdf.
135. Press Release, Families USA, New Report Links High Prescription Drug Prices
to Marketing Costs, Profits, and Enormous Executive Compensation (July 10, 2001),
available at http://www.familiesusa.org/resources/newsroom/press-releases/press-release
-new-report-links-high-prescription-drug-prices-to-marketing-costs-profits-and-
enormous-executive-compensation.html (last visited July 31, 2006).
136. FAMILIES USA, OFF THE CHARTS: PAY, PROFITS AND SPENDING By DRUG
COMPANIES 3 (2001), available at http://www.familiesusa.org/assets/pdfs/offthecharts
6475.pdf.
137. See Pharmaceutical Companies Maintain Huge Profits with High-Priced Pills,
supra note 134.
138. FAMILIES USA, supra note 135.
139. But see JIM GILBERT & PAUL ROSENBERG, BAIN & CO., IMBALANCED INNOVATION
(2004), available at http://www.bain.com/bainweb/PDFs/cms/Marketing/addressing
innovation divide.pdf.
140. FAMILIES USA, supra note 135.
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IV. PENDING FEDERAL LEGISLATION: POSSIBLE SOLUTIONS?
A. The House proposal
On July 24, 2003, the U.S. House of Representatives passed the
Pharmaceutical Market Access Act of 2003 (PMAA). 141 Co-sponsored by
34 Republicans and 18 Democrats, 142 the PMAA was bipartisan in nature.
The PMAA does the following:
1) Amends the Federal FD&C Act to direct FDA to promulgate
regulations allowing qualifying individuals to import prescription drugs (in
addition to pharmacists and wholesalers, whom current law authorizes to
import drugs). 1
43
2) Amends the provision regarding record keeping of imported
prescription drugs. The FDA is no longer required to store records in
circumstances where qualifying individuals have imported prescription
drugs. 1
44
3) Amends the provision related to prescription drug importation,
including the removal of a former FDA requirement that foreign sellers
specify the original source of the product and the amount of each lot of the
product originally received. 1
45
4) Amends provisions pertaining to imported prescription drug testing.
Specified tests, including ones involving authenticity and degradation, shall• • 146
not be required unless the importer is a wholesaler.
5) Requires the importer to conduct such tests unless a product is a
prescription drug subject to counterfeit-resistant packaging provisions




Following a 243 to 186 passage of the PMAA in the House, 148 a bipartisan
effort emerged in the Senate. Introduced on April 24, 2004, the
141. Pharmaceutical Market Access Act of 2003, H.R. 2427, 108th Cong. (2003).
142. Id.





148. H.R. 2427, supra note 114.
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Pharmaceutical Market Access and Drug Safety Act of 2004 (Dorgan-
Snowe) does the following:
149
1) Amends the Federal FD&C Act to revise provisions governing the
importation of prescription drugs.
1 50
2) Requires the FDA to promulgate regulations allowing the importation
of prescription drugs by registered exporters/importers from Canada within
90 days of passage and within one year from Australia, European Union
countries, Japan, New Zealand, or Switzerland.'
5'
3) Provides for inspection, tracking of drugs, and registration and
inspection fees for registered exporters/importers.
4) Requires manufacturers to: (1) submit a statement to the FDA
explaining each difference between a drug approved and distributed in the
U.S. and a related drug distributed in a foreign country; and (2) submit an
application for FDA approval of a related drug distributed in a foreign
country if there is, in at least half of the permitted countries, no comparable
drug already approved for importation to the U.S.
15 3
5) Allows for the immediate importation of prescription drugs for personal
use from licensed Canadian pharmacies.' 54
6) Amends the Clayton Act 155 to prohibit drug manufacturers from
preventing importation by engaging in behavior such as charging higher
prices or limiting supplies to registered exporters and importers or changing
the form of the drug for such purpose.'
56
2. Gregg-Smith
On June 2, 2004, Senate Republicans introduced the Safe Importation of
Medical Products and Other Rx Therapies Act of 2004 or Safe IMPORT Act
of 2004 (Gregg-Smith). 157 The Gregg-Smith bill would amend the Federal
FD&C Act158 to:
149. Dorgan-Snowe, supra note 2.





155. 15 U.S.C. §§ 12-27, 44 (2005).
156. Dorgan-Snowe, supra note 2, at § 4.
157. Safe Importation of Medical Products and Other Rx Therapies Act of 2004, S.
2493, 108th Cong. (2004) [hereinafter Gregg-Smith].
158. 21 U.S.C. § 301 (2005).
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1) Allow individuals to import FDA-approved prescription drugs from
Canada for personal use.'
59
2) Permit the importation of prescription drugs from Canada by registered
Internet pharmacies, pharmacies, or wholesalers one year after enactment of
the Act under specified conditions, including meeting proper labeling on all
dispensed drugs to indicate that the drug has been imported.
160
3) Allow the FDA to designate additional countries from which to allow
importation after three years.1
4) Require the FDA to give high priority to improving its information
management systems to enhance detection of intentionally adulterated
prescription drugs. 1
62
5) Set forth Internet pharmacy licensing requirements and procedures.
163
6) Make providers of interactive computer and advertising services liable
for violations under the Act if such providers: (1) accept a prescription drug
from an unlicensed Internet pharmacy; or (2) accept advertising stating that
an individual does not need a physician's prescription to obtain a
prescription drug.' 
64
7) Require the FDA to promulgate regulations requiring designated
payment systems, including credit card companies, to prevent sales by
unlicensed Internet pharmacies.165
8) Allow the FDA to (1) detain or temporarily hold prescription drug
shipments based on credible information that a drug presents a risk to the
public health; 166 (2) suspend importation of a particular drug or dosage that
poses such a risk or by a particular importer who violates Act
requirements;167 (3) for repeated or serious violation, debarpersons from
importing or offering for importation a prescription drug; 168 (4) require
owners of prescription drugs that have been refused admission into the U.S.
to indicate that information on the drug containers; 169 and (5) authorize other
Federal and State officials to conduct inspections to enforce compliance with
the Act.
170
159. Gregg-Smith, supra note 130, at § 2.
160. Id. at § 2.
161. Id.
162. Id. at § 3.
163. Id. at § 4.
164. Id. at § 4.
165. Id.
166. Id. § 5.
167. Id. §6.
168. Id. § 7.
169. Id. § 11.
170. Id. § 5.
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8) Deems to be misbranded a prescription drug offered for importation
that has previously been refused admission, unless the person reoffering the
drug affirmatively establishes that it complies with applicable
requirements.1
7 1
V. CONFUSING A PRICING ISSUE WITH A REGULATORY ISSUE
The U.S. prescription drug supply has long been regarded as one of the
safest in the world-the so-called "gold standard." This is in no small part
attributable to the diligent efforts of the FDA. Any legislative efforts to
open our "closed" drug distribution system by legalizing importation should
not be taken lightly. If Congress insists on legalizing large scale drug
importation, it must afford FDA the additional authority and resources
necessary to ensure all drugs are safe and effective.172 This would be a
massive undertaking for the FDA, one that may be impossible to implement
either logistically or financially. Which begs the question, should
importation be legalized at all?
Individual consumers would be wise to heed FDA warnings of potentially
dangerous or ineffective drugs when resorting to questionable Internet sites
or mail-order pharmacies. 73 Trips to Canada to purchase brand-name drugs
from licensed, reputable Canadian pharmacies should not pose any
additional risks to the American consumer. 17 4 Unfortunately, cross-border
travel is not the method most use to obtain their drugs. Instead, an
increasingly large percentage of illegal irmportation occurs via unregulated
and sometimes fraudulent Internet sites. These sites have, in some
documented cases, filled orders with unsafe or ineffective drugs often
complicating patient illness or disease. 176
Logistically, FDA would face extreme and possibly insurmountable
hurdles if ordered to implement a regulatory framework for personal drug
importation. The FDA maintains the "gold standard" by inspecting domestic
and foreign facilities manufacturing drugs bound for U.S. distribution. Such
inspections are only logistically and financially feasible by inspecting drugs
en masse at the point of development, manufacture, and distribution. If the
FDA were expected to inspect and ensure the safety of every personal drug
171. Id. § 11.




176. FDA News, U.S. Food & Drug Admin., FDA Test Results of Prescription Drugs
from Bogus Canadian Website Show All Products Are Fake and Substandard (July 13,
2004), available at http://www.fda.gov/bbs/topics/news/2004iNEWOI087.html.
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imported, from several countries and countless facilities around the world, it
would almost surely fail in its mission to maintain the "gold standard."'
' 77
It is estimated that any savings from legalized drug importation would be
a fractional percentage of total drug spending in the U.S. 178 Any legalized
importation system would require development of significant infrastructure
to facilitate the safe delivery of drugs to the American consumer.179
Additional safety measures beyond FDA's current capabilities would be
required. 10 The costs of drug regulation would rise, likely offsetting any
savings to consumers. 181 Moreover, intermediaries would likely retain a
significant percentage of any savings intended for consumers. Foreign
governments and pharmaceutical suppliers could restrict supplies to
exporting pharmacies to choke off U.S. drug importation.1 83 Only the
Dorgan-Snowe 84 bill even addresses U.S. pharmaceutical companies
restricting supply to foreign pharmacies re-importing to the U.S. by making
such retaliatory actions illegal. Congress does not have jurisdiction over
foreign governments or pharmaceutical companies and would be unable to
prevent any retaliatory action in the form of supply constraints.
Largely ignored in the current debate is the fact that many generic drugs
sold in the U.S. cost less then their foreign counterparts. 18  While U.S.
brand-name drugs are undoubtedly overpriced and unaffordable to some,
generic drugs provide a cost-effective alternative. Consumers should be
encouraged to "[s]hop[] around for price comparisons, ask[] a doctor or
pharmacist for a generic alternative to a prescribed brand name drug, or
us[e] a Medicare or other prescription drug discount card."'' 86 By utilizing
any of the above methods consumers can lower their monthly prescription
drug bill while ensuring they receive safe and effective drugs. 1
Any large scale legalized importation will undoubtedly reduce
pharmaceutical company revenues. Most pharmaceutical companies reap
profits commensurate with the overpriced American brand-name drug
market. If consumers are able to circumvent high domestic prices for low





182. Id. See also Antony, supra note 129.
183. HHS TASK FORCE ON DRUG IMPORTATION, supra note 7, at XIII.
184. Dorgan-Snowe, supra note 2.
185. HHS TASK FORCE ON DRUG IMPORTATION, supra note 7, at XIII. See also OFFICE
OF PLANNING, U.S. FOOD & DRUG ADMIN., FDA WHITE PAPER, supra note 124.
186. HHS TASK FORCE ON DRUG IMPORTATION, supra note 7, at XIII.
187. Id.
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cost price-controlled drugs from Canada, revenues decrease. As revenues
decrease, pharmaceutical companies contend they will reduce spending on
research and development of new drugs.18 8 The industry estimates that as
many as 18 new drugs per decade could fail to reach market if research is cut
due to decreased revenues following legalized importation. Is9 While it is
difficult to concern oneself with pharmaceutical companies' financial
wellbeing, any reduction in development of new drugs is a serious threat to
everyone's public health.
Although the pharmaceutical industry's contentions are cause for concern,
upon further analysis they may be refuted. Pharmaceutical companies
routinely spend twice as much on marketing and advertising compared to
expenditures on research and development.190  Consumers could
undoubtedly live without Viagra commercials in exchange for increased
spending on research and development or lower prescription drug prices.
Reduced prices result in decreased spending on research and development
only if the industry continues gluttonous spending on marketing and
executive compensation' 9' to the detriment of U.S. consumers.
VI. LEGALIZED IMPORTATION NOT A SOLUTION: THE CASE FOR
ALTERNATIVE REFORM
A Congressional proposal for legalized drug importation has reached a
variety of findings such as: "Americans unjustly pay up to 1000 percent
more to fill their prescriptions than consumers in other countries;"192 "[t]he
United States is the world's largest market for pharmaceuticals yet
consumers still pay the world's highest prices;"'193 "[a]llowing and
structuring the importation of prescription drugs ensures access to affordable
drugs...;,'1 4 "American seniors alone will spend $1.8 trillion.., on
pharmaceuticals over the next ten years;"'195 and "[a]llowing open
188. Antony, supra note 129.
189. Id. See also HHS TASK FORCE ON DRUG IMPORTATION, supra note 7, at XIII.
190. See Pharmaceutical Companies Maintain Huge Profits with High-Priced Pills,
supra note 134.
191. FAMILIES USA, supra note 135..
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pharmaceutical markets could save American consumers at least $635
billion.., each year."
'1 96
These are compelling statistics. However, cost considerations have never
driven FDA policy. The FDA ensures all domestically marketed
prescription drugs are safe and effective. The unbearably high cost of
prescription drugs is due to a lack of government price controls and an
expensive research and development process.
Something must be done to lower the cost of prescription drugs, but at
what price? Are Americans willing to sacrifice the "gold standard" we
currently enjoy to obtain affordable drugs? Americans are turning to foreign
price-controlled countries, in ever-increasing numbers, for an affordable
alternative. It is undoubtedly a trade-off: sacrificing the security of the
FDA-assured "gold standard" for the uncertain safety and efficacy of lower-
priced foreign drugs. Americans are demanding answers to the dilemma and
Congress is attempting to respond. But is legalized importation really the
answer?
The two competing Senate bills, Dorgan-Snowe 197 and Gregg-Smith, 198
employ necessary safety measures but are different in several key ways.
Dorgan-Snowe contains provisions prohibiting U.S. pharmaceuticals from
engaging in retaliatory behavior such as raising prices or limiting supplies to
foreign pharmacies re-importing to U.S. consumers. Gregg-Smith contains
no such provision and leaves open the possibility that pharmaceuticals can
choke off supply to Canadian pharmacies exporting to U.S. consumers.
199
Dorgan-Snowe allows for immediate drug importation from Canada and
eventually other developed nations while Gregg-Smith sets a delayed
timetable and asks for further FDA study. Notably, Dorgan-Snowe puts
much of the onus for inspection, tracking, and registration of imported drugs
on exporters and manufacturers while Gregg-Smith places the bulk of the
burden on FDA. The Gregg-Smith approach could overwhelm the FDA
logistically. The provisions of Dorgan-Snowe, placing additional burdens
on exporters and manufacturers, will only pass on the increased costs to
consumers, negating any cost savings and defeating the purpose of
196. Id.
197. Dorgan-Snowe, supra note 2.
198. Gregg-Smith, supra note 130.
199. In fact, pharmaceuticals are doing just that. See Glaxo Threatens to Boycott
Canada: Senior, Consumer Groups Threaten to Boycott GlaxoSmithKline,
CONSUMERAFFARIS.COM, Jan. 17, 2003, http://consumeraffairs.com/news03/glaxo.html.
See also Patricia Barry, Drug Companies Cut Canadian Supply, AARP BULLETIN
ONLINE, Apr. 2004, http://www.aarp.org/bulletin/prescription/Articles/a2004-03-25-
cut.html.
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importation in the first place. The various proposals are a noble effort to
address a significant problem but are flawed in many respects.
All of the above leads one to ask do we need legalized importation at all?
Should Congress impose additional burdens on the FDA, thereby
endangering drug safety, to cut costs for Americans in need of costly drugs?
Should Congress establish a drug importation infrastructure run by
intermediaries who will consume potential cost-savings before such savings
reach consumers? The fundamental problem with legalized importation is
that it is a short term solution to a long term problem. Americans do not
want Canadian drugs; they want Canadian prices. Congress should forego
ill-conceived legalization schemes. Instead, Congress needs to take on the
formidable pharmaceutical lobby and figure out a way to establish some
form of price-controls.
Congress could take one of several steps in an effort to bring down prices.
First, impose limited price controls through the Centers for Medicare &
Medicaid Services (CMS), the agency responsible for administering these
programs. By using the mass participation in Medicare as negotiating
leverage to drive down prices, CMS could have a positive effect in lowering
prescription drug prices, at least for the millions of seniors participating in
the program. 20 Next, Congress could do more to subsidize research and
development to drive down the cost of discovering new drugs. 20 1 This would
lead to lower prescription drug prices or at least negate the pharmaceutical
companies' argument that the high cost of research and development drives
the need for high prices.
20 2
Thus, when it comes to legalizing drug importation, Congress should do
nothing. The current proposals, as written, either ask too much of the FDA
or pass the costs of importation on to manufacturers and pharmacies,
ultimately defeating importation's rationale--cost-savings for consumers. If
Congress wants to show it is serious about helping those suffering from high
prescription drug prices it must work towards a long term solution-
negotiated price-controls for those participating in Medicare and Medicaid
and increased federal subsidies for research and development. The effort to
200. Patricia Barry, Pushing Down Drug Costs: AARP Opens Drive to Lower Drug
Prices With a Range of Fixes to New Medicare Law, AARP BULLETIN ONLINE, Feb.
2004, http://www.aarp.org/bulletin/prescription/Articles/a2004-02-18-drugcosts.html.
201. However, Congress already appropriates more then $28.4 billion annually to
NIH, the Federal focal point for health research (approximate NIH budget for 2005 was
$28,495,157,000). NAT'L INST. OF HEALTH, THE NIH ALMANAC-APPROPRIATIONS,
available at http://www.nih.gov/about/almanac/appropriations/part2.htm.
202. Press Release, Geralyn Ritter, Vice President, International Affairs,
Pharmaceutical Research and Manufacturers of America, on OECD Pharmaceutical
Study (Dec. 21, 2004), available at http://international.phrma.org/mediaroom/press/
releases/21.12.2004.1107.cfm.
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legalize drug importation is nothing more then a short term solution to the
long term problem of unaffordable prescription drugs and should not
proceed.
CONCLUSION
While Congressional efforts to "solve" the problem are admirable, they do
little more then temporarily pacify a long term problem. How can
Americans continue to enjoy the FDA-ensured "gold standard" without
being denied prescription drugs due to cost? Imposing additional burdens on
the FDA and weakening the "gold standard" is not the answer. Congress
must do the hard work in overcoming the pharmaceutical lobby to prevent
future disaster. Americans should not have to resort to Internet pharmacies
or bus trips across the border to obtain affordable prescription drugs. For
decades, the FDA has ensured safe and effective drugs through its vigilance.
Congress should not jeopardize the safety of Americans by bowing to the
political pressure of "drugs at any cost."
